Evidence map›Paper›PMID 41512872›Full record

ArticleCell stem cell2026

Nanoengineered 3D culture substrate enables superior persistence and polyclonal engraftment of genetically engineered hematopoietic stem cells.

Federico Midena, Laura Alessandrini, Claudio Conci, Matteo Barcella, Francesco Gazzo, Emanuela Jacchetti, Edoardo Carsana, Fabrizio Benedicenti, Roberta Vacca, Lucrezia Della Volpe and 26 more

Abstract read
In one paragraph

Article in Cell stem cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors.

Federico MidenaSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy.
Laura AlessandriniSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy.
Claudio ConciDepartment of Chemistry, Materials, and Chemical Engineering "Giulio Natta," Politecnico di Milano, 20133 Milan, Italy.
Matteo BarcellaSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Francesco GazzoSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Department of Electronics, Information, and Bioengineering, Politecnico di Milano, 20133 Milan, Italy.
Emanuela JacchettiDepartment of Chemistry, Materials, and Chemical Engineering "Giulio Natta," Politecnico di Milano, 20133 Milan, Italy.
Edoardo CarsanaSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Fabrizio BenedicentiSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Roberta VaccaSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy.
Lucrezia Della VolpeSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Sergio ArévaloSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Kety GiannettiSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Dafne BarozziDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Martina FranchinoVita-Salute San Raffaele University, 20132 Milan, Italy; Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Erika ZonariSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Francesca FerruaSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Giacomo FarinaSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; University of Milan-Bicocca, 20126 Milan, Italy.
Chiara BrombinCUSSB - University Center for Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Federica CugnataCUSSB - University Center for Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Martina FiumaraSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Teresa TavellaSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Leonardo CherubinDepartment of Chemistry, Materials, and Chemical Engineering "Giulio Natta," Politecnico di Milano, 20133 Milan, Italy.
Federico FraschettaPediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Giulio CerulloDepartment of Physics, Politecnico di Milano, 20133 Milan, Italy; National Research Council, Institute for Photonics and Nanotechnologies (IFN-CNR), 20133 Milan, Italy.
Roberto OsellameNational Research Council, Institute for Photonics and Nanotechnologies (IFN-CNR), 20133 Milan, Italy.
Marina RadrizzaniSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Samuele FerrariSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Ivan MerelliSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; National Research Council, Institute for Biomedical Technologies, 20054 Segrate, Italy.
Bernhard GentnerSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Ludwig Institute for Cancer Research and Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
Cristina ScielzoDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Andrea BrendolanDivision of Experimental Oncology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Luigi NaldiniSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy.
Alessandro AiutiSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy; Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Eugenio MontiniSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Manuela T RaimondiDepartment of Chemistry, Materials, and Chemical Engineering "Giulio Natta," Politecnico di Milano, 20133 Milan, Italy.
Raffaella Di MiccoSan Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; University School of Advanced Studies IUSS, 27100 Pavia, Italy. Electronic address: dimicco.raffaella@hsr.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ex vivo culture of hematopoietic stem and progenitor cells (HSPCs) is required for gene therapy applications but inadvertently triggers detrimental cellular responses, potentially threatening clinical success. In this study, we employ nichoids, biocompatible 3D culture substrates with cell-scale resolution, to provide HSPCs with mechanical support during ex vivo manipulation. This innovative 3D system improves HSPC multi-lineage differentiation and engraftment capacity by leveraging mechanobiological control over nuclear morphology, cytoskeleton organization, metabolism, and DNA integrity. Notably, 3D culture enables efficient genetic engineering across multiple platforms, including long-range gene editing, base- and prime-editing, and lentiviral-mediated gene addition. Moreover, this scaffold increases the clonal output and persistence of genetically engineered cells in xenotransplantation experiments, including a clinical protocol for lentiviral gene addition in Wiskott-Aldrich syndrome. Overall, we propose a transformative approach to enhance the efficacy and safety of emerging and established hematopoietic stem cell-based gene therapy applications.

Indexed as

Cell Culture Techniques, Three DimensionalGenetic EngineeringHematopoietic Stem CellsHematopoietic Stem Cell TransplantationAnimalsCell DifferentiationGene EditingHumansLentivirusMice3D cultureclonal trackinggenome editinghematopoietic stem cellslentiviral gene transfermechanobiologyWiskott-Aldrich syndrome

Identifiers

PMID41512872
PMCPMC12904609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.